FibroGen to Present Financial Results for Q3 2024
FibroGen, Inc. (NASDAQ: FGEN), a key player in the biopharmaceutical industry, is gearing up to announce its financial results for the third quarter of 2024. This significant update will happen soon after the market closes. This conference will be crucial, as it provides deep insights into the company's financial health and corporate strategies.
Conference Call Details
The conference call will take place on Tuesday at 5:00 PM Eastern Time, where executive leaders will engage with the investment community. It is recommended that participants dial in at least five minutes prior to the start to ensure they don’t miss any important information. The call will be accessible using the provided toll-free and international numbers.
How to Join the Call
Participants can join the call by using the following numbers: for listeners in the U.S., dial the toll-free number 1-877-300-8521, while international investors can reach the conference at 1-412-317-6026. It’s important to be punctual, as this will allow participants to absorb all the relevant information from the presentation.
Webcast Availability
For those who can't join live, a replay of the webcast will be made available for a limited time. Details for accessing the playback will be posted on the FibroGen website under the Events and Presentation section after the call.
Company Overview
Founded with the mission to pioneer novel therapies, FibroGen, Inc. is at the forefront of biopharmaceutical innovation, especially in the area of cancer biology. Their flagship product, Roxadustat, is currently utilized across multiple regions including China and Europe to treat anemia in patients with chronic kidney disease. This therapy is particularly significant for those undergoing dialysis.
Current Drug Development Initiatives
As part of advancing their pipeline, FibroGen is actively developing Roxadustat for chemotherapy-induced anemia, alongside other therapies aimed at treating complex cancers. Notably, they are working on FG-3246 (FOR46), an innovative antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer. This comprehensive approach epitomizes FibroGen's commitment to addressing critical unmet medical needs.
Research and Development Expansion
The company is also diversifying its research portfolio to include promising immuno-oncology candidates targeting solid tumors, demonstrating FibroGen's forward-thinking strategy and dedication to enhancing patient care through advanced treatments.
Contact Information for Investor Inquiries
For interested investors seeking more information, David DeLucia, the Vice President of Corporate FP&A and Investor Relations, is available to provide insights. Investors are encouraged to reach out directly for inquiries.
Frequently Asked Questions
What date will FibroGen announce its Q3 2024 results?
FibroGen will announce its third quarter results after market close on November 12.
How can I listen in on the conference call?
Listeners can dial the appropriate telephone number at least five minutes before the start of the call to participate.
Will a recording of the call be available?
Yes, a replay of the webcast will be hosted on FibroGen's website for a limited period.
What is Roxadustat used for?
Roxadustat is approved for treating anemia in patients with chronic kidney disease both on and off dialysis.
Who can I contact for investor questions?
David DeLucia, Vice President of Corporate FP&A / Investor Relations, is the contact person for investor inquiries.
